白细胞介素-28B附近基因多态性与慢性丙型肝炎的抗病毒治疗相关性的研究进展_West China Medical Journal

Authors：

徐辉 ,  雷学忠

Corresponding author：

雷学忠, Email: sir_blues@sohu.com

Keywords：

丙型肝炎病毒; 白细胞介素-28B; 单核苷酸多态性; 预测疗效

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

【摘要】 白细胞介素-28B（IL-28B）是一种重要的细胞因子，也被称之为干扰素-λ3 （IFN-λ3），其作用机制类似于IFN-α，通过诱导受体异二聚体化，活化JAK-STAT信号通路，进而发挥抗病毒、免疫调节等生物学作用。最近国外研究团队相继发现IL-28B基因附近的单核苷酸多态性与干扰素联合利巴韦林治疗慢性丙型病毒性肝炎的疗效密切相关。这有助于通过宿主基因水平更准确的预测患者治疗效果，并有可能在将来提供一种更有效的治疗方案。

Citation： 徐辉,雷学忠. 白细胞介素-28B附近基因多态性与慢性丙型肝炎的抗病毒治疗相关性的研究进展. West China Medical Journal, 2011, 26(1): 139-141. doi: Copy

1.	Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update[J]. Hepatology, 2009, 49(4): 1335-1374.
2.	Amin J, Dore GJ, O’connell DL, et al. Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study[J]. J Hepatol, 2006, 45(2): 197-203.
3.	Zeuzem S, Berg T, Moeller B, et al. Expert opinion on the treatment of patients with chronic hepatitis C[J]. J Viral Hepatitis, 2009, 16(2): 75-90.
4.	Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C - A randomized study of treatment duration and ribavirin dose[J]. Ann Intern Med, 2004, 140(5): 346-355.
5.	Liu CH, Liu CJ, Lin CL, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial[J]. Clin Infect Dis, 2008, 47(10): 1260-1269.
6.	Yan KK, Guirgis M, Dinh T, et al. Treatment responses in Asians and Caucasians with chronic hepatitis C infection[J]. World J Gastroenterol, 2008, 14(21): 3416-3420.
7.	Sheppard P, Kindsvogel W, Xu WF, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R[J]. Nat Immunol, 2003, 4(1): 63-68.
8.	Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambda s mediate antiviral protection through a distinct class II cytokine receptor complex[J]. Nat Immunol, 2003, 4(1): 69-77.
9.	Ge DL, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance[J]. Nature, 2009, 461(7262): 399-401.
10.	Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus[J]. Nature, 2009, 461(7265): 798-801.
11.	Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication[J]. J Virol, 2005, 79(6): 3851-3854.
12.	Ank N, West H, Bartholdy C, et al. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo[J]. J Virol, 2006, 80(9): 4501-4509.
13.	Marcello T, Grakoui A, Barba-spaeth G, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics[J]. Gastroenterology, 2006, 131(6): 1887-1898.
14.	Suppiah V, Moldowan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy[J]. Nat Genet, 2009, 41(10): 1100-1174.
15.	Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C[J]. Na Genet, 2009, 41(10): 1105-1181.

1. 　Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update[J]. Hepatology, 2009, 49(4): 1335-1374.
2. 　Amin J, Dore GJ, O’connell DL, et al. Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study[J]. J Hepatol, 2006, 45(2): 197-203.
3. 　Zeuzem S, Berg T, Moeller B, et al. Expert opinion on the treatment of patients with chronic hepatitis C[J]. J Viral Hepatitis, 2009, 16(2): 75-90.
4. 　Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C - A randomized study of treatment duration and ribavirin dose[J]. Ann Intern Med, 2004, 140(5): 346-355.
5. 　Liu CH, Liu CJ, Lin CL, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial[J]. Clin Infect Dis, 2008, 47(10): 1260-1269.
6. 　Yan KK, Guirgis M, Dinh T, et al. Treatment responses in Asians and Caucasians with chronic hepatitis C infection[J]. World J Gastroenterol, 2008, 14(21): 3416-3420.
7. 　Sheppard P, Kindsvogel W, Xu WF, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R[J]. Nat Immunol, 2003, 4(1): 63-68.
8. 　Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambda s mediate antiviral protection through a distinct class II cytokine receptor complex[J]. Nat Immunol, 2003, 4(1): 69-77.
9. 　Ge DL, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance[J]. Nature, 2009, 461(7262): 399-401.
10. 　Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus[J]. Nature, 2009, 461(7265): 798-801.
11. 　Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication[J]. J Virol, 2005, 79(6): 3851-3854.
12. 　Ank N, West H, Bartholdy C, et al. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo[J]. J Virol, 2006, 80(9): 4501-4509.
13. 　Marcello T, Grakoui A, Barba-spaeth G, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics[J]. Gastroenterology, 2006, 131(6): 1887-1898.
14. 　Suppiah V, Moldowan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy[J]. Nat Genet, 2009, 41(10): 1100-1174.
15. 　Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C[J]. Na Genet, 2009, 41(10): 1105-1181.

West China Medical Journal

白细胞介素-28B附近基因多态性与慢性丙型肝炎的抗病毒治疗相关性的研究进展

Abstract Full text Figures/Tables Video References Cited by

Format

Content